ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 957,57
0,54%
Dow Jones
38 675,68
1,18%
DAX
18 001,60
0,54%
Brent Oil
83,035
-0,11%
Bitcoin
63 857,66
-0,22%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Centogene NV (CNTG)

  7. Centogene NV (CNTG) Actualités

CNTG Centogene NV

0,4406
0,0066 (1,52%)
04 Mai 2024 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Centogene NV CNTG NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
0,0066 1,52% 0,4406 06:00:02
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
0,438 0,43 0,4557 0,442851 0,434
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
02/4/202422:30GLOBECENTOGENE Receives Nasdaq Non-Compliance Notice
19/3/202411:30GLOBECENTOGENE Extends Strategic Partnership With Takeda to..
29/2/202423:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
29/2/202423:00GLOBECENTOGENE Collaborates on Research Published in Science..
28/2/202412:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
28/2/202412:30GLOBECENTOGENE Announces Receipt of Nasdaq Notice of Delisting..
28/2/202412:30GLOBECENTOGENE Explores Strategic Alternatives
28/2/202412:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
25/1/202412:30GLOBECENTOGENE and the Laboratory of Human Genetics of Infectious..
25/1/202412:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
24/1/202412:30GLOBECENTOGENE Receives French Research Tax Credit Accreditation
24/1/202412:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
23/1/202412:36EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
23/1/202412:30GLOBECENTOGENE and The Michael J. Fox Foundation Announce..
18/1/202413:02EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
18/1/202412:30GLOBECENTOGENE Announces Preliminary Full Year 2023 Revenue
19/12/202313:10EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
19/12/202312:30GLOBECENTOGENE Announces Voting Results of Extraordinary General..
18/12/202312:41EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
13/12/202312:33EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
13/12/202312:30GLOBECENTOGENE’s Frontotemporal Dementia (FTD) Genetic Study,..
01/12/202312:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
28/11/202312:30GLOBECENTOGENE and Lifera, a Public Investment Fund (PIF)..
28/11/202312:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
14/11/202314:30GLOBECENTOGENE, University College London, and Global Team of..
03/11/202321:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
27/10/202313:28EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
10/10/202312:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
10/10/202312:30GLOBECENTOGENE Expands Multiomic Diagnostic Portfolio With..
06/10/202322:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
11/9/202314:30GLOBECENTOGENE to Present at H.C. Wainwright 25th Annual Global..
07/9/202323:00GLOBECENTOGENE Reports First Half 2023 Financial Results
07/9/202323:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
01/9/202314:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
01/9/202314:00GLOBECENTOGENE Announces Publication Establishing Lyso-Gb1 as a..
31/8/202322:30GLOBECENTOGENE Receives Nasdaq Non-Compliance Notification..
31/8/202322:08EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
18/8/202322:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
07/8/202312:30GLOBECENTOGENE to Participate in Upcoming Conferences in August
14/7/202312:31EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
14/7/202312:30GLOBECENTOGENE Regains Compliance With Nasdaq Listing..
12/7/202313:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
12/7/202313:30GLOBECENTOGENE Biodatabank Reveals Unique Genetic Variants in..
02/7/202311:00PRNUSLifera and CENTOGENE, Enter Strategic Collaboration -..
30/6/202322:31EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
30/6/202322:30GLOBECENTOGENE Announces Approval of All Resolutions Tabled at..
27/6/202313:30GLOBECENTOGENE and Lifera, a Biopharma Company Owned by the PIF,..
14/6/202322:30GLOBECENTOGENE Receives Nasdaq Notification Regarding Minimum..
17/5/202300:25GLOBECENTOGENE Reports Full Year 2022 Financial Results

Dernières Valeurs Consultées

NASDAQ
CNTG
Centogene NV
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés